Kornimate/medical-research-clean huggingface dataset:
application of sticky bone and bio-oss collagen in alveolar ridge preservation

Conditions: Alveolar Bone Resorption

Summary: in this experiment, after non-traumatic tooth extraction, the blank group underwent natural healing, and the control group underwent alveolar ridge preservation using bio-oss collagen and the experimental group using sticky bone, to verify the application of bio-oss collagen and sticky bone in alveolar ridge preservation

within 6 months after tooth extraction, the remaining alveolar ridge undergoes varying degrees of absorption, resulting in a decrease in horizontal width and vertical height of the alveolar ridge. the three-dimensional size change of the alveolar socket may affect the implantation of later implants and cause aesthetic and functional problems. alveolar ridge preservation can maintain the volume of the alveolar socket, prevent soft tissue from growing into undesirable positions, slow down the absorption of the alveolar ridge to some extent, promote new bone formation, and maintain the shape of the extraction socket. this is crucial for later implant treatment for missing teeth. in this experiment, after non-traumatic tooth extraction, the blank group underwent natural healing, and the control group underwent alveolar ridge preservation using bio-oss collagen and the experimental group using sticky bone, respectively, to verify the application of bio-oss collagen and sticky bone in alveolar ridge preservation

Eligibility criteria:
inclusion criteria: 1. the presence of one adjacent tooth at the extraction site 2. adequate oral hygiene (plaque index \<20%;bleeding on probing \<25% ) 3. need for tooth extraction due to endodontic，periapical or periodontal disease. 4. presence of ≥ 2 mm of keratinized tissue 5. the extraction sockets have no more than 50% of buccal alveolar bone loss(integrity of alveolar bone walls) exclusion criteria: 1. pregnancy or lactation 2. smoking more than 10 cigarettes per day 3. with no evidence of acute infection such as severe swelling, suppuration at the extraction site 4. uncontrolled periodontal disease 5. existence of bone metabolic disease 6. history of malignancy, radiotherapy, or chemotherapy in the past 5 years 7. administration of bisphosphonates 8. long-term use of nsaids 9. alcohol or drug abuse 10. infectious disease, such as hepatitis or human immunodeficiency virus (hiv) and/or acquired immunodeficiency syndrome (aids) 11. uncontrolled severe diabetes.( hemoglobin a1c \>6.7%)

Keywords: alveolar ridge preservation bio-oss collagen sticky bone
research study for treatment of children and adolescents with acute myeloid leukaemia 0-18 years

Conditions: Pediatric Acute Myeloblastic Leukemia

Summary: this study evaluates the effect of different induction courses in children and adolescents with newly diagnosed acute myeloid leukemia. in the first course patients are randomised to receive either standard anthracycline therapy with mitoxantrone or experimental daunoxome. in the second course patients are randomised between standard treatment with adxe (cytarabine, daunoxome, etoposide) or experimental therapy with fladx (fludarabine, cytarabine, daunoxome).


Eligibility criteria:
inclusion criteria: 1. aml as defined by the who diagnostic criteria 2. age \< 19 years at time of diagnosis 3. written informed consent exclusion criteria: 1. previous chemotherapy or radiotherapy. this includes patient with secondary aml after previous cancer therapy 2. aml secondary to previous bone marrow failure syndrome. 3. down syndrome (ds) 4. acute promyelocytic leukaemia (apl) 5. myelodysplastic syndrome (mds) 6. juvenile myelomonocytic leukaemia (jmml) 7. known intolerance to any of the chemotherapeutic drugs in the protocol. 8. fanconi anaemia 9. major organ failure precluding administration of planned chemotherapy. 10. positive pregnancy test 11. lactating female or female of childbearing potential not using adequate contraception
treatment effect of intense pulsed light and thermal pulsation therapy on meibomian gland dysfunction-associated dry eye disease: a randomized trial

Conditions: Dry Eye Disease (DED); Meibomian Gland Dysfunction

Summary: the goal of this clinical trial is to understand novel treatment methods for meibomian gland dysfunction (mgd)-associated dry eye disease (ded) by comparing two treatment modalities- intense pulsed light (ipl) and thermal pulsation therapy (tpt), to find out the difference of their therapeutic mechanisms and treatment effects, so that eye doctors can give more precise advice to the patients when making treatment decisions. the main questions it aims to answer are: * what subtype of meibomian gland dysfunction (mgd) better responds to which treatment modality? * how long do the treatment effects last? researchers will compare each group (ipl and tpt) to a control group treated with eyedrops. \* do combined treatment of ipl or tpt with eyedrops show better outcomes than only eyedrops? participants will: * receive different treatment for 2 months according to the group they were randomly allocated to. * visit the clinic for checkups after 1 and 3 months after completing the treatment sessions.


Eligibility criteria:
inclusion criteria: * individuals diagnosed with meibomian gland dysfunction (mdg)-associated dry eye disease (ded) that are suitable for intense pulsed light (ipl) and thermal pulsation therapy (tpt) exclusion criteria: * ocular surgery or trauma in the recent 3 months * ocular infection * eyelid abnormalities (e.g., entropion, ectropion, lagophthalmos, severe ptosis or trichiasis) * blepharospasm * eyelid tumor * severe meibomian gland atrophy * allergic to topical anesthetics * sunbathe in recent one month * periocular fillers
efficacy and safety study of bls_ilb_e710c for the fertile women with cervical intraepithelial neoplasia(cin3)

Conditions: Cervical Intraepithelial Neoplasia

Summary: the purpose of this study is to determine the efficacy and the safety of bls-ilb-e710c for the the fertile women with cervical intraepithelial neoplasia (cin3).

this study is to see the regression rate of cervical intraepithelial neoplasia (cin3) and to see the inducement of cytotoxic t lymphocyte. the first treatment group will be administered with bls-ilb-e710c 500mg for 8 weeks followed by 1 week observation the second treatment group will be administered with bls-ilb-e710c 1000mg for 8 weeks followed by 1 week observation the third treatment group will be administered with bls-ilb-e710c 1500mg for 8 weeks followed by 1 week observation the fourth treatment group will be administered with bls-ilb-e710c optimum dose for 8 weeks followed by 8 weeks observation

Eligibility criteria:
inclusion criteria: * pre-menopausal patients between age of 20 and 50. * patients with cervical intraepithelial neoplasia 3(cin3). * only infection with hpv type 16. * patients with capable of observation of all of lesions by colposcopy biopsy. * be informed of the nature of the study and will give written informed consent. * be agree with contraception during study * white blood cell count(wbc) over 4thous/ul, hemoglobin above over 9.0g/dl platelet over 150thous/ul and anc(absolute neutrophil count) over 1,500 /mm\^3 * normal for ekg(electrocardiography) * ast/alt : 2.5 times less than normal range exclusion criteria: * autoimmune disease or prohibited drug(therapy) bring about immunosuppressive. * patient that has medical history of hypersensitivity about food containing lactic acid bacteria or lactic acid bacteria medication. * patient with acute illness(ex. acute appendicitis, myocardial infarction, hemorrhage, meningitis etc.) * investigational product within three months before the start of the drug administration to patients treated with other test drug. * patient with chronic pancreatitis currently or patients diagnosed with acute pancreatitis. * organopathy patient with inflammatory intestine·bowel disease, gastrointestinal tumors, ulcers, bleeding, perforation etc. * pregnant or lactating women * patient with hbv or hcv infection (except for asymptomatic) * patient that investigator judge * deemed inappropriate for researchers to judge the patient

Keywords: treatment of cervical intraepithelial neoplasia(cin3)
visco-circumferential-suture-trabeculotomy versus trabeculotomy

Conditions: Primary Congenital Glaucoma

Summary: comparing outcomes of visco-circumferential-suture-trabeculotomy in primary congenital glaucoma to trabeculotomy

prospective randomized interventional study conducted on infants below the age of 2 years with pcg attending the outpatient clinic of mansoura ophthalmic center of mansoura university were recruited to compare the long-term surgical outcomes of this proposed technique (vcst) and rigid probe vt in patients with pcg.

Eligibility criteria:
inclusion criteria: * infants below the age of 2 years with pcg exclusion criteria: * patients older than 2 years on presentation * eyes with previous surgery * eyes with secondary glaucoma * eyes diagnosed as anterior segment dysgenesis syndrome
protection of corneal epithelium using chitosan-n-acetylcysteine eye drops during and/or after cataract surgery

Conditions: Eye Diseases

Summary: the aim of this study is to assess if treatment with lacrimera® eye drops (croma-pharma gbmh, leobendorf, austria) during and/ or after cataract surgery has a positive effect on the ocular surface compared to control group.

prior to surgery, pre-assessment measurements will be performed in the same fashion as for non-study patients. patients will be randomized to one of the 3 groups in a 1:1:1 fashion using an online randomization tool (www.randomizer.org, list randomizer). surgery is performed in topical anaesthesia. right after topical anaesthesia, patients allocated to group 3 will receive 1 drop of lacrimera® in the study eye. injection of viscoelastic substance (ovd), capsulorhexis, phacoemulsification, and coaxial irrigation/ aspiration of cortical material are performed as standard procedure. after iol implantation the ovd will be removed and at the end of the surgery, stromal hydration will be performed to the incision as a routine procedure to seal the wound. right after the wound is sealed, patients allocated to group 2 and group 3 will receive 1 drop of lacrimera® in the study eye. postoperative standard medication (bromfenac gtt., twice a day for 4 weeks) will be prescribed for all groups.

Eligibility criteria:
inclusion criteria: * age 22 or older * scheduled for cataract surgery * normal findings in the medical history and physical examination unless the investigator considers an abnormality to be clinically irrelevant * written informed consent prior to surgery exclusion criteria: * relevant other ophthalmic diseases such as pseudoexfoliation syndrome (pex), intraoperative floppy iris syndrome (ifis), cornea pathology (e.g. corneal scars, etc.) * usage of eye drops other than lubricants (e.g. antibiotics, steroids, cyclosporin-a) * previous ocular surgery or trauma in the study eye within 6 months of the cataract surgery * active ocular infection or inflammation * pregnancy (pregnancy test will be taken in women of reproductive age) * subjects with surgery longer than 30 minutes will be excluded and replaced
twist human gene and cleft lips and palates

Conditions: Cleft Lip

Summary: this study uses a sequence analysis for twist and other craniofacial development genes, among patients presenting with facial clefting.


Eligibility criteria:
inclusion criteria: patients aged from 1 month to 18 years: * parents agree to enrollment or patients, themselves, agree to enrollment when able to do so * healthcare insurance holders * display facial clefting grown patients over 18 years of age: * agree to enrollment * display facial clefting * healthcare insurance holders exclusion criteria: * patients declining enrollment * patients without healthcare insurance

Keywords: facial clefting twist craniofacial development genes human cleft lip and palate cleft lip and palate
fluorescence imaging on the da vinci surgical system for intraoperative near infrared imaging

Conditions: Renal Tumors

Summary: a prospective investigation of the use of the fluorescence imaging on the da vinci surgical system for intraoperative near infrared imaging of renal cortical tumors. to determine the feasibility of the fluorescence imaging on the da vinci surgical system in robotic partial nephrectomy procedures and report perioperative outcomes.


Eligibility criteria:
inclusion criteria: * ages of 18 to 80 years. * urine pregnancy test negative for women of childbearing potential prior to surgery * subject is able to comply with the study procedures * a ct or mri preoperative assessment of renal cortical tumor * the renal tumor must be stage t1a-b - t2 * written informed consent. exclusion criteria: * subject has significant liver disease, cirrhosis or liver insufficiency with abnormal liver function tests, as total bilirubin \>1.5 x normal and/or sgot \>2x normal * subject has uremia, serum creatinine \>2.0 mg/dl. * subject has a previous history of adverse reaction or allergy to icg, iodine, shellfish or iodine dyes * subject in whom the use of x-ray dye or icg is contraindicated including development of adverse events when previously or presently administered * subject has any medical condition, which in the judgment of the investigator and/or designee makes the subject a poor candidate for the investigational procedure * subject is pregnant or lactating * subjects actively participating in another drug, biologic and/or device protocol * the presence of medical conditions contraindicating general anesthesia or standard surgical approaches.
a 2-part study to assess local tolerability, safety and pharmacokinetics of ceftaroline in healthy subjects

Conditions: Healthy

Summary: the purpose of this study is to assess the safety, tolerability, and pharmacokinetics of ceftaroline 600 mg when administered by varying infusion volumes.

a phase i, single-center, 2-part, randomized, 2-way crossover study to assess the local tolerability and safety (multiple-dose) and to assess the pharmacokinetics, safety, and tolerability (single-dose) of ceftaroline in healthy subjects when ceftaroline fosamil is diluted in various infusion volume

Eligibility criteria:
inclusion criteria: * provision of informed consent prior to any study specific requirements * women of childbearing potential must have a negative pregnancy test, be non-lactating, and be using a highly effective form of birth control for 3 months prior to enrollment, during the study, and for 3 months after completion of all study-related proceed * male volunteers must be willing to use barrier contraception from the first day of dosing until 3 months after the last dose of ip. * have a body mass index (bmi) between 18 and 30 kg/m2, and weigh at least 50 kg * healthy male and/or female volunteers between the ages of 18 to 75 years inclusive, with veins on the back of both hands and both forearms suitable for cannulation or repeated venipuncture. exclusion criteria: * use of any other investigational compound or participation in another clinical trial within 1 month prior to first administration of ip in this study * history of any clinically significant disease or disorder (e.g., neurological, haematological, psychiatric, gastrointestinal, hepatic, renal disease) * positive serology result on screening for serum hepatitis b surface antigen, hepatitis c antibody (hcv), or human immunodeficiency virus (hiv) * history or presence of gastrointestinal, hepatic, or renal disease or any other condition known to interfere with the absorption, distribution, metabolism or excretion of drugs * any clinically significant abnormalities in the physical examination, lab, 12-lead ecg or vital signs as judged by the investigator

Keywords: phase 1 healthy volunteers cross-over study ceftaroline fosamil various infusion volumes local tolerability cmax tmax auc
examination of cognitive function in patients treated with subutex

Conditions: Opiate Addiction

Summary: people who addicted to heroin and other opiates suffer from a disease with approved genetic basis. it causes to a behavioral response as searching and using those drugs even though they know it causes severe damages as physiological, familiar and legal affairs. the popular treatment's goal is to "clean" the people from any drug. in a medical and pharmacological point of view there is no sense in this approach for all people. this point of view believes that buprenorphine (subutex) is a correct pharmacological treatment. the hypothesis of this research is that people using buprenorphine have difficulties in gaining weight, in sexual and cognitive function (according to subjects' reports)

people who addicted to heroin and other opiates suffer from a disease with approved genetic basis. it causes to a behavioral response as searching and using those drugs even though they know it causes severe damages as physiological, familiar and legal affairs. the popular treatment's goal is to "clean" the people from any drug. in a medical and pharmacological point of view there is no sense in this approach for all people. this point of view believes that buprenorphine (subutex) is a correct pharmacological treatment. the hypothesis of this research is that people using buprenorphine have difficulties in gaining weight, in sexual and cognitive function (according to subjects' reports) we examine people who stopped opiates and began buprenorphine. every participant in the study will have two visits: the first one before receiving buprenorphine and the second one after 3 months of receiving buprenorphine.

Eligibility criteria:
inclusion criteria: * people who suffer from addiction problems (opiates) * people who willing to to start buprenorphine treatment * people who willing to cooperate with study tests and questionnaires * people aged 18 to 70 exclusion criteria: * people who suffer from any neurocognitive problems * people who suffer from mental illnesses * people who are having legal guardian

Keywords: opiates subutex buprenorphine patients who addicted to opiates
evaluation of verbal and visual information techniques

Conditions: Anxiety

Summary: the aim of this study is to evaluate the effects of preoperative and postoperative anxiety levels on patients using oral information, visual information with surgical photographs and visual information via audio-video. to evaluate anxiety levels, dental anxiety scale (das), modified dental anxiety scale (mdas) and state anxiety scale (stai-s, stai-t) scales will be used.

after giving written information about the study, an informed consent form will be distributed to patients who want to participate in the study and they will be asked to sign it. patients who have signed the consent form will be asked to complete the das, mdas, stai-t and stai-s questionnaires in the waiting room to assess preoperative anxiety levels. verbal, photos and video information used to inform patients. patients will be randomly divided into 3 groups. a total of 60 patients with 20 patients in each group will be included in the study. patients in all groups will be operated by the same surgeon. oral information will be given to the patients in the first group. in the second group, visual information will be given to the patients by showing the photos of the operation process. patients in group 3 will also be shown a video of an audio implant operation showing the operation process. the operation video of a previously implanted patient will be watched by the attending physician. this video will begin with the physician informing the patient about the implant and continue with anesthesia. afterward, the video will be terminated by giving information about the implant operation video and the complications that the patient may encounter and the points to be considered after the operation. a 7-day pain score will be obtained using the smiley vas scale to measure postoperative pain levels and patients will be asked to note how many painkillers they use. in addition, blood pressure and pulse measurements will be taken before and after surgery. a common text was prepared in all groups in order to provide preoperative information in an ideal way. in group 1, information related to this text will be given orally. in the 2nd and 3rd groups, patients will be informed about the same information as well as visuality.

Eligibility criteria:
inclusion criteria: * patients admitted to the investigator's clinic for implant surgery exclusion criteria: * pregnant patients * patients using psychiatric drugs * patients with visual problems
respiratory virus metagenomics after covid-19

Conditions: COVID-19 Respiratory Infection

Summary: the study aims to characterize the distributive pattern of viruses in upper airway and its relationship with influenza seasons, symptomatology and exposure setting. a total of 500 adults residing in hong kong would be recruited, who would complete a questionnaire and return self-collected nasal and throat swabs for metagenomic analyses.

1. this is a serial cross-sectional study. participants would be asked to complete a questionnaire and to self-collect nasal and throat swabs during a specified collection period with reference to an influenza season. 2. subjects would be invited by post through randomly selected households throughout the territory of hong kong. eligible persons are adults normally resident in the address who could communicate in written chinese or english. persons incapable of giving informed consent would be excluded. other exclusion criteria are: individuals with mental illnesses, prisoners. approval is obtained from the clinical research ethics committee. 3. a bilingual questionnaire would be administered, which consists of four parts, including: (a) socio-demographics; (b) history of sars-cov-1 infection and vaccination; (c) exposure settings preceding sample collection; (d) presence and types (if any) of influenza-like illnesses (ili) at the time of sample collection; 4. with the provision of nasal and throat swab collection kits, participants shall collect the nasal/throat sample within a 3-month period from the start of an influenza season when one presents with influenza-like illnesses (ili), or at the end of the season if no such illnesses occur. the self-collected swabs would need to be returned with the questionnaire within 48 hours after sampling. after returning the swabs, a hk$50 voucher would be given to compensate participants' time. 5. rna would be extracted from the collected samples, followed by by metagenomic analyses. the collected data would be tidied, checked and collated to form a research database. descriptive statistics, including standard frequency tables and metrics, would be performed. 6. the key outcomes in this study are the change of abundance of viruses in different influenza seasons, and the difference in distributions of viral taxa in samples from participants. 7. on completion of the analyses, the transmission risk of respiratory infections could be assessed, and emerging viral infections could be identified. certain exposure setting associated viruses could be identified to inform public health policies.

Eligibility criteria:
inclusion criteria: * adults normally residing in hong kong * could communicate in english and/or chinese * provision of consent exclusion criteria: * individuals with mental illness * prisoners

Keywords: metagenomic respiratory virus infections exposure risk